International Journal of Scientific Research in Dental and Medical Sciences

International Journal of Scientific Research in Dental and Medical Sciences

Nanoparticle-Based Doxorubicin Delivery for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.

Document Type : Review Article

Authors
Maryam Fathi 1
Parsa Eshragh Abad Shapori 2
Farina Golnama 3
1 Antoine Béclère hospital Faculty of Health Sciences of Sorbonne, paris, France
2 Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran
3 School of Medicine, Sechenov University, Moscow, Russia
10.30485/ijsrdms.2026.572431.1698
Abstract
Background and aim: Triple-negative breast cancer (TNBC) is challenging due to its aggressive nature and limited targeted therapies. Doxorubicin-loaded nanoparticles have been proposed as a novel strategy to increase treatment efficacy and reduce side effects. This study aimed to conduct the first meta-analysis to evaluate the efficacy of these systems in in vitro and in-vivo TNBC models.
Material and methods: This study was conducted as a systematic review and meta-analysis. A systematic search of reputable scientific databases was conducted to identify studies published over the last 10 years, from January 2015 to September 2025. Eligible studies included those reporting quantitative data related to cell viability, IC50, and tumor volume reduction. Meta-analyses were performed using a random-effects model (DerSimonian–Laird), and subgroup analyses were conducted by nanoparticle type and TNBC cell model.
Results: A total of 8 eligible studies, including 15 datasets, were included in the meta-analysis. Doxorubicin-loaded nanoparticles resulted in a significant reduction in cell viability (effect size = 0.44), with more pronounced effects observed in FZD7-targeted nanoparticles and the MDA-MB-231 cell line. IC50 analysis indicated that exosome-based nanoparticles and polymeric nanoparticles exhibited the lowest IC50 values, reflecting enhanced drug cytotoxicity. Additionally, in vivo data demonstrated a significant reduction in tumor volume (effect size = 0.44), particularly for FZD7-targeted nanoparticles and sol–gel doxorubicin nanoparticles.
Conclusions: Doxorubicin-loaded nanoparticles significantly enhance TNBC treatment efficacy in vitro and in animal models, providing strong quantitative evidence for the development and clinical translation of these systems.
Keywords
Doxorubicin
Nanoparticle Drug Delivery System
Triple Negative Breast Neoplasms
Subjects
[1] Elhawary NA, Ekram SN, Sembawa HA, Tashkandi E, Bannani S, Azher ZA, et al. Descriptive epidemiology of female breast cancer around the world: incidence, mortality, and sociodemographic risks and disparities. International Journal of Environmental Health Research. 2025;35(12):3648-62. https://doi.org/10.1080/09603123.2025.2492826.
[2] Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nature medicine. 2025;31(4):1154-62. https://doi.org/10.1038/s41591-025-03502-3.
[3] Sood D, Kaur C, Kumar N, Kumar R, Singh G. Triple-negative breast cancer: challenges, advances, and promising therapeutic interventions. Medical Oncology. 2025;42(11):506. https://doi.org/10.1007/s12032-025-03066-9.
[4] Ratanaphan A. Therapeutic Potential of Metal-Based and PARP Inhibitor Chemotherapy for BRCA1-Associated Triple-Negative Breast Cancer. International Journal of Molecular Sciences. 2025;26(20):9881. https://doi.org/10.3390/ijms26209881.
[5] Rane BR, Sawant RR, Mhatre PV, Kothawade SN. Introduction of triple negative breast cancer and precision medicine. InArtificial Intelligence-Driven Precision Medicine for Triple Negative Breast Cancer. 2026;3-23. https://doi.org/10.1016/B978-0-443-33565-5.00004-9.
[6] Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. Journal of hematology & oncology. 2022;15(1):121. https://doi.org/10.1186/s13045-022-01341-0.
[7] Bisht A, Avinash D, Sahu KK, Patel P, Das Gupta G, Kurmi BD. A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer. Drug Delivery and Translational Research. 2025;15(1):102-33. https://doi.org/10.1007/s13346-024-01648-0.
[8] Gote V, Nookala AR, Bolla PK, Pal D. Drug resistance in metastatic breast cancer: tumor targeted nanomedicine to the rescue. International journal of molecular sciences. 2021;22(9):4673. https://doi.org/10.3390/ijms22094673.
[9] Zeng W, Luo Y, Gan D, Zhang Y, Deng H, Liu G. Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer. Frontiers in bioengineering and biotechnology. 2023;11:1271420. https://doi.org/10.3389/fbioe.2023.1271420.
[10] Tugwell P, Tovey D. PRISMA 2020. Journal of Clinical Epidemiology. 2021;134:A5-6. https://doi.org/10.1016/j.jclinepi.2021.04.008.
[11] Hoover EC, Ruggiero OM, Swingler RN, Day ES. FZD7-targeted nanoparticles to enhance doxorubicin treatment of triple-negative breast cancer. ACS omega. 2024;9(12):14323-35. https://doi.org/10.1021/acsomega.3c10275.
[12] Sarkar R, Biswas S, Ghosh R, Samanta P, Pakhira S, Mondal M, et al. Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3, 3′-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer. Journal of Nanobiotechnology. 2024;22(1):285. https://doi.org/10.1186/s12951-024-02518-0.
[13] Zhang C, Tang S, Wang M, Li L, Li J, Wang D, et al. “Triple-punch” strategy exosome-mimetic nanovesicles for triple negative breast cancer therapy. ACS nano. 2024;18(7):5470-82. https://doi.org/10.1021/acsnano.3c10568.
[14] Wei R, Fu G, Li Z, Liu Y, Qi L, Liu K, et al. Au-Fe3O4 Janus nanoparticles for imaging-guided near infrared-enhanced ferroptosis therapy in triple negative breast cancer. Journal of Colloid and Interface Science. 2024;663:644-55. https://doi.org/10.1016/j.jcis.2024.02.201.
[15] Cavanagh RJ, Monteiro PF, Moloney C, Travanut A, Mehradnia F, Taresco V, et al. Free drug and ROS-responsive nanoparticle delivery of synergistic doxorubicin and olaparib combinations to triple negative breast cancer models. Biomaterials Science. 2024;12(7):1822-40.
[16] Zhang M, Bao S, Qiu G, Liang J, Wang Q, Zhu X, et al. An magnetic-targeting nano-diagnosis and treatment platform for TNBC. Breast Cancer: Targets and Therapy. 2023:101-19. https://doi.org/10.2147/BCTT.S387793.
[17] Zhou J, Li K, Zang X, Xie Y, Song J, Chen X. ROS-responsive galactosylated-nanoparticles with doxorubicin entrapment for triple negative breast cancer therapy. International Journal of Nanomedicine. 2023:1381-97. https://doi.org/10.2147/IJN.S396087.
[18] Krausz AE, Adler BL, Makdisi J, Schairer D, Rosen J, Landriscina A, et al. Nanoparticle-encapsulated doxorubicin demonstrates superior tumor cell kill in triple negative breast cancer subtypes intrinsically resistant to doxorubicin. Precision nanomedicine. 2018;1(3):173-82. https://doi.org/10.33218/prnano1(3).181029.1.
[19] Ramayanam NR, Bukke SP, Moka MK, Dehingia H, Bordoloi A, Debbarma R, et al. Advances in nanoparticle-based doxorubicin delivery: precision strategies for targeted treatment of triple-negative breast cancer. Discover nano. 2025;20(1):111. https://doi.org/10.1186/s11671-025-04308-5.
[20] Sen S, Xavier J, Kumar N, Ahmad MZ, Ranjan OP. Exosomes as natural nanocarrier-based drug delivery system: recent insights and future perspectives. 3 Biotech. 2023;13(3):101. https://doi.org/10.1007/s13205-023-03521-2.
[21] Choi MJ, Lee YK, Choi KC, Lee DH, Jeong HY, Kang SJ, et al. Tumor-targeted erythrocyte membrane nanoparticles for theranostics of triple-negative breast cancer. Pharmaceutics. 2023;15(2):350. https://doi.org/10.3390/pharmaceutics15020350.
International Journal of Scientific Research in Dental and Medical Sciences
Volume 7, Issue 4
Autumn 2025
Pages 190-196

  • Receive Date 08 October 2025
  • Revise Date 29 November 2025
  • Accept Date 03 December 2025
  • Publish Date 01 December 2025